Leukemia, Myeloid, Acute Clinical Trial
Official title:
An Open Phase I Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Cafusertib Hydrochloride in Combination With Subcutaneous Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)
NCT number | NCT02140606 |
Other study ID # | HS-10159-I-01 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 1 |
First received | May 12, 2014 |
Last updated | May 13, 2014 |
Start date | May 2014 |
To investigate safety, tolerability of cafusertib combination with low dose cytarabine (LD-Ara-C) in Chinese patients with relapsed/refractory AML that are not eligible for conventional or intensive treatment. The dose of cafusertib will be escalated to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of cafusertib in combination with LD-Ara-C in AML patients. At the same time, pharmacokinetic characteristics and preliminary efficacy of cafusertib will be observed in AML patients. To determine the recommended dosage regimen for phase II.
Status | Recruiting |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Signed written informed consent consistent with Chinese Good Clinical Practice. - Male or female patients of age >/= 18 years at the time of informed consent. - Patients with relapsed/refractory AML ineligible for conventional or intensive treatment. - Eastern Cooperative Oncology Group performance status score 0 - 2 at screening. - Life expectancy of at least 3 months. - Adequate hepatic, renal and metabolic function parameters: Serum total bilirubin =1.5 x upper limit of normal, aspartate transaminase (AST) , alanine transaminase (ALT) =2.5 x upper limit of normal; Creatinine clearance rate =60ml/min, Serum creatinine =1.0 x upper limit of normal; Relatively normal ECG(electrocardiogram), QTc<450 ms(male) ,QTc<470 ms(female); LVEF>50%. - Patients who can comply with the trial and follow-up procedures. Exclusion Criteria: - Patients had received cafusertib hydrochloride or other PLK inhibitors. - Patients with APL. - Patients with central nervous system leukemia. - Need to continue using cytokine therapy at screening. - Patients participated in other clinical trials within 4 weeks prior to enrollment. - Patient with severe infection. - Patients with myocardial infarction had occurred within six months prior to enrollment. - Severe heart disease, including NYHA class II cardiac dysfunction and above. - Patients with HIV infection or acute and chronic viral hepatitis. - Severe gastrointestinal disorders (bleeding, infection, obstruction or greater than grade 1 diarrhea). - A previous history of neurological or psychiatric disorders, including epilepsy or dementia. - Concomitant medications with CYP3A4 inhibitors, inducers or substrates; Women pregnant or breast feeding. - Subject is thought unfit for this study by investigator. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Hospital of Blood Diseases, Chinese Academy of Medical Sciences | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MTD of cafusertib in combination with LDAraC based on the incidence of dose limiting toxicities | 4 weeks | Yes | |
Secondary | Efficacy (complete remission, CR; complete remission with incomplete blood count recovery, Cri; Partial remission (PR)) | minimum 4 weeks, maximum n.a. | No | |
Secondary | Incidence and intensity of adverse events graded according to CTCAE (version 4.0) | minimum 4 weeks, maximum n.a. | No | |
Secondary | Incidence of dose limiting toxicity (DLT) | 4 weeks | Yes | |
Secondary | Pharmacokinetics of cafusertib | 4 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05319587 -
Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04090736 -
Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy
|
Phase 3 | |
Completed |
NCT01617226 -
Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS
|
Phase 2 | |
Terminated |
NCT00916045 -
Pilot Study of Unrelated Cord Blood Transplantation
|
Phase 2 | |
Terminated |
NCT00957580 -
Trial of Pimasertib in Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00640796 -
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
|
Phase 1 | |
Completed |
NCT00458250 -
Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H
|
Phase 1 | |
Active, not recruiting |
NCT05424380 -
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
|
Phase 1 | |
Completed |
NCT01690624 -
BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse
|
Phase 1 | |
Recruiting |
NCT05471700 -
Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05016063 -
Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
|
Early Phase 1 | |
Not yet recruiting |
NCT04450784 -
ObServatory Children Acute RElated Therapy Leukemia
|
||
Recruiting |
NCT04265963 -
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Terminated |
NCT04968860 -
Oral Health Condition and Quality of Life in Children With Leukemia
|
||
Recruiting |
NCT03793517 -
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
|
Phase 2/Phase 3 | |
Terminated |
NCT02841540 -
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
|
Phase 1 | |
Recruiting |
NCT05453903 -
A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
|
Phase 1 | |
Completed |
NCT03720366 -
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
|
Phase 1 | |
Withdrawn |
NCT04230564 -
Acute Myeloid Leukemia Real World Treatment Patterns
|
||
Terminated |
NCT03761069 -
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
|
Phase 1 |